Drug Profile
Pegloprastide - Avelas Biosciences
Alternative Names: Activated cell penetrating peptide - Avelas Biosciences; AVB-620; Fluorescent probe - Avelas Biosciences; Fluorescent protease-activated peptide - Avelas Biosciences; Fluroscent peptide conjugate-Avelas BiosciencesLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Avelas BioSciences
- Class Diagnostic agents; Diagnostic conjugates; Imaging agents; Peptide diagnostics
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
- Phase II Colorectal cancer; Head and neck cancer; Malignant melanoma; Ovarian cancer; Sarcoma
Most Recent Events
- 28 Sep 2022 Phase II development is still ongoing for Colorectal cancer (Diagnosis), Head and neck cancer (Diagnosis), Malignant melanoma (Diagnosis), Ovarian cancer (Diagnosis), Sarcoma (Diagnosis) in USA (IV) (Avelas Biosciences pipeline, September 2022)
- 28 Sep 2022 Phase III development is still ongoing for Breast cancer (Diagnosis) in USA (IV) (Avelas BioSciences pipeline, September 2022)
- 18 Oct 2021 Avelas Biosciences plans a registrational confirmatory phase III trial for Breast cancer (Diagnosis) in the first half of 2022